Cancer Treat Rev 38: pp. 494-504Ahmad Awada,Ivana Bozovic-Spasojevic,Louis Chow.New therapies in HER2-positive breast cancer: A major step towards a cure of the disease?[J]. Cancer Treatment Reviews .2012(5)Awada A, Bozovic-Spasojevic I, Chow L. New therapies in HER2-positive breast ...
“There have been many advances in the development of drugs for HER2-positive breast cancer since the introduction of Herceptin (trastuzumab) in 1998. The approval of Enhertu represents the newest treatment option for patients who have progressed on available HER2-directed therapi...
Over the past 18 months, the FDA has approved 4 new regimens for HER2-positive metastatic disease.In an interview with Pharmacy Times, Kelly Gaertner, PharmD, an oncology clinical pharmacy specialist with Allegheny Health Network, said that a slew of new treat...
Next, O’Shaughnessy reviewed recent developments in the treatment of HER2-positive breast cancer. Tucatinib very selectively inhibits HER2, she said, allowing it to get great brain penetration. The randomized HER2CLIMB trial saw not only improvements in progression-free survival (PFS), but also...
The UK has conditionally approved Enhertu® (trastuzumab deruxtecan) as a monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer based on Phase II trial results...
Discovery Of Gene That Causes HER2 Breast Cancer To Spread Raises Hope For New TreatmentScientists in Scotland have identified a gene that plays a key role in the spread of HER2 positive to other parts of the body, raising hopes of a new treatment for this common form of breast cancer....
HER2‐positive breast cancerT‐DM1trastuzumabtucatinibBackground Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)﹑ositive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous ...
7 Tripathy said it was interesting “the outcome was so much better in the T-DM1—based treatment group.” The results led the FDA to expand indications for T-DM1 in May 2019 to include patients with early-stage HER2-positive breast cancer and residual invasive disease after neoadjuvant ...
Resistance to therapy is a major problem in the cancer field. Even when a treatment initially works, the tumors often find ways around the therapy. Using human cell lines of the HER2-positive breast cancer subtype, researchers from the UNC School of Medicine and UNC Lineberger Comprehensive Canc...
"Mitochondrial creatine kinase 1 may be a new drug target for the treatment of HER2 positive breast cancer," says Matthew Goetz, M.D., director of the Mayo Clinic Breast Cancer research program. "Future clinical trials will be necessary to determine the effectiveness of thisdrugfor HER2 positiv...